Mid-cap investors see Eastern promise in the third quarter
Turbulence in Japan made the country’s biopharma industry a relatively safe haven – but clinical success or setbacks dictated the fortunes of most mid and small-cap…
Buyers of cancer assets fan the licensing deal market
The price of early stage cancer assets leaves Celgene shelling out $3.5bn in upfront payments, with no end in sight for rising valuations.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.